Impact of Dosing and Administration on HRQoL Among People With Hemophilia: A Time Trade-Off Study Including 2.250 Respondents in the UK, Canada and the US

Speaker(s)

Wolden M1, Yssing C2, Wahid MN1, Okkels A2
1Novo Nordisk A/S, Søborg, Denmark, 2EY, Frederiksberg, Denmark

Presentation Documents

OBJECTIVES: Hemophilia is a bleeding disorder characterized by spontaneous bleedings due to deficiency of clotting factor. The most common site for bleeds is the joints which can be painful and may restrict daily activities. Current treatments are administered as subcutaneous (SC) injections or intravenous (IV) infusions with varying treatment frequencies. Treatment is lifelong, and it is therefore crucial to minimize treatment burden. The aim of this study was to investigate the treatment impact on HRQoL.

METHODS: Time trade-off methodology was used to estimate utilities through an online survey completed by the general population. Respondents evaluated health states as if they were living with hemophilia and treated themselves with prophylactic treatment. The following aspects were evaluated: frequency, device complexity (administration, preparation steps and time-use) and injection site reactions.

RESULTS: In total, 812, 739 and 703 respondents completed the survey in the UK, Canada and the US, respectively. The results suggest that device complexity is key. Using a pre-filled pen device for SC injections once every month (QM) was associated with a significant utility gain of 0.03 in all three countries when compared to a syringe for SC injections QM (p<0.001, CI 95% UK: 0.021-0.040, Canada: 0.020-0.040, US: 0.019-0.044). Furthermore, it was associated with a significant utility gain of 0.6 in the UK and of 0.4 in Canada and the US when compared to weekly IV treatment options (p<0.001, CI 95% UK: CI 95% 0.049-0.070, Canada: 0.026-0.056, US: 0.029-0.059). Additionally, the results indicate that less frequent treatments and treatments not associated with injection site reactions have the potential to increase HRQoL.

CONCLUSIONS: Different aspects of hemophilia treatment have an impact. Future treatments should focus on easy-to-use devices that require few preparation steps and a short time-use (including preparation and administration). This could lead to improvements in HRQoL among people with hemophilia.

Code

PCR89

Topic

Medical Technologies, Methodological & Statistical Research, Patient-Centered Research

Topic Subcategory

Health State Utilities, Medical Devices, Patient-reported Outcomes & Quality of Life Outcomes, Survey Methods

Disease

No Additional Disease & Conditions/Specialized Treatment Areas, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)